《大行報告》高盛對內地醫藥股H股投資評級及目標價(表)
高盛發表研究報告,對內地醫藥股H股投資評級及目標價修訂表列如下:
股份?投資評級?目標價(港元)
藥明生物(02269.HK)?買入→確信買入?157.9→170.7元
諾誠健華-B(09969.HK) ?買入?21→33元
基石藥業-B(02616.HK) ?買入?14.8→18元
康哲藥業(00867.HK)?中性?14.43→18.23元
翰森製藥(03692.HK)?買入?41.3→36.4元
復星醫藥(02196.HK)?買入→中性?39→72.11元
嘉和生物-B(06998.HK)?買入→中性?24.91→14.85元
海普瑞(09989.HK)?買入→中性?17.6→12.16元
三生製藥(01530.HK)?買入→中性?9.3→8.1元
威高股份(01066.HK)?買入→中性?15.48→16.4元
方達控股(01521.HK)?買入→中性?5.79→6.96元
國藥控股(01099.HK)?買入→中性?26→23.4元
華潤醫藥(03320.HK)?買入→中性?5.9→4.89元
聯邦製藥(03933.HK)?中性→沽售?6.5→5.82元
上海醫藥(02607.HK)?中性→沽售?17.6→16.6元
歌禮制藥-B(01672.HK)?中性→沽售?3.75→2.45元
高盛對其餘覆蓋內地醫藥股H股投資評級及目標價表列如下:
股份?投資評級?目標價(港元)
華領醫藥-B(02552.HK)?買入?12.7元
兆科眼科-B(06622.HK)?買入?20.29元
藥明巨諾-B(02126.HK)?買入?35.64元
科濟藥業-B(02171.HK)?買入?48.72元
中生製藥(01177.HK)?買入?11.8元
啓明醫療-B(02500.HK)?買入?70.77元
德琪醫藥-B(06996.HK)?買入?23.45元
歐康維視生物-B(01477.HK)?買入?35.78元
雲頂新耀-B(01952.HK)?買入?93.77元
愛康醫療(01789.HK)?買入?14.6元
康基醫療(09997.HK)?買入?15.5元
加科思-B(01167.HK)?買入?26.05元
諾輝健康-B(06606.HK)?買入?89.66元
信達生物(01801.HK)?買入?100.3元
康龍化成(03759.HK)?買入?227.8元
石藥集團(01093.HK)?買入?13.5元
麗珠醫藥(01513.HK)?中性?37.7元
藥明康德(02359.HK)?買入?214.3元
時代天使(06699.HK)?中性?408元
白雲山(00874.HK)?沽售?20.2元
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.